cancer biology
Bone healing therapy for NF1 fractures
Sep. 11, 2014—A combination treatment delivered to the site of fractures may improve bone healing in patients with the genetic disease neurofibromatosis type-1.
Limiting breast cancer metastasis
Aug. 28, 2014—Vanderbilt researchers have identified a new target for blocking breast cancer metastasis.
Growth factor blockade targets breast tumors
Aug. 14, 2014—Inhibition of BMP growth factor signaling reduces breast tumor burden and metastasis.
Novel treatment strengthens bones in genetic disease
Aug. 7, 2014—An enzyme therapy may prevent skeletal abnormalities associated with the genetic disorder neurofibromatosis type-1, Vanderbilt investigators have discovered.
Drug discovery clues in network map
Aug. 5, 2014—Vanderbilt investigators have constructed a network map that could guide the development of new targeted cancer therapies.
Repair protein’s DNA recognition motif
May. 23, 2014—Insights into the workings of DNA damage response proteins such as SMARCAL1 could suggest new ways to improve genome integrity and prevent cancer.
Potential mechanism for myeloma drug’s variable toxicity
Apr. 30, 2014—A genetic variant is associated with toxicity of the chemotherapy drug melphalan, and could guide individualized dosing for the medication.
Study links stem cell gene to prostate cancer susceptibility
Mar. 27, 2014—A gene on chromosome 8 — in a region of the genome linked to risk for many types of cancer — is particularly associated with prostate cancer susceptibility, Vanderbilt University researchers have found.
New direction for treating lung cancer
Feb. 7, 2014—Targeting the production of molecules that promote tumor blood vessel development offers a new path for treating lung cancer.
Cancer cells combine tools to increase invasiveness
Dec. 19, 2013—Two features of invasive cancer cells — invadopodia and exosomes — are linked together, Vanderbilt University investigators have discovered.
Therapeutic target for gastric cancer
Dec. 12, 2013—A protein kinase linked to inflammation and tumor development may be a good target for gastric cancer therapies.
Therapeutic target for synovial sarcoma
Nov. 21, 2013—Inhibitors of a signaling pathway that is critical to synovial sarcoma tumorigenesis may be useful treatments for this aggressive cancer.